Nanjing Medlander Medical Technology Co. Ltd. A
Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation product, and sports rehabilitation products, as well as consumables products, such as vagina… Read more
Nanjing Medlander Medical Technology Co. Ltd. A (688273) - Total Assets
Latest total assets as of June 2025: CN¥1.52 Billion CNY
Based on the latest financial reports, Nanjing Medlander Medical Technology Co. Ltd. A (688273) holds total assets worth CN¥1.52 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nanjing Medlander Medical Technology Co. Ltd. A - Total Assets Trend (2020–2024)
This chart illustrates how Nanjing Medlander Medical Technology Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nanjing Medlander Medical Technology Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Nanjing Medlander Medical Technology Co. Ltd. A's total assets of CN¥1.52 Billion consist of 64.8% current assets and 35.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 29.8% |
| Accounts Receivable | CN¥15.18 Million | 1.0% |
| Inventory | CN¥73.05 Million | 4.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥60.55 Million | 3.9% |
| Goodwill | CN¥41.90 Million | 2.7% |
Asset Composition Trend (2020–2024)
This chart illustrates how Nanjing Medlander Medical Technology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanjing Medlander Medical Technology Co. Ltd. A's current assets represent 64.8% of total assets in 2024, an increase from 58.8% in 2020.
- Cash Position: Cash and equivalents constituted 29.8% of total assets in 2024, down from 44.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 4.7% of total assets.
Nanjing Medlander Medical Technology Co. Ltd. A Competitors by Total Assets
Key competitors of Nanjing Medlander Medical Technology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Nanjing Medlander Medical Technology Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nanjing Medlander Medical Technology Co. Ltd. A generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Nanjing Medlander Medical Technology Co. Ltd. A generates $6.57 in net profit.
Nanjing Medlander Medical Technology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.88 | 9.39 | 16.82 |
| Quick Ratio | 7.31 | 8.93 | 16.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥803.93 Million | CN¥ 963.61 Million | CN¥ 1.24 Billion |
Nanjing Medlander Medical Technology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Nanjing Medlander Medical Technology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.30 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | CN¥1.55 Billion |
| Market Capitalization | $218.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nanjing Medlander Medical Technology Co. Ltd. A's assets below their book value (0.14 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nanjing Medlander Medical Technology Co. Ltd. A's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nanjing Medlander Medical Technology Co. Ltd. A (2020–2024)
The table below shows the annual total assets of Nanjing Medlander Medical Technology Co. Ltd. A from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.55 Billion | +0.83% |
| 2023-12-31 | CN¥1.53 Billion | +1.46% |
| 2022-12-31 | CN¥1.51 Billion | +209.35% |
| 2021-12-31 | CN¥488.74 Million | +45.39% |
| 2020-12-31 | CN¥336.15 Million | -- |